20cm Express | Biotechnology and Pharmaceuticals Elevated to Emerging Pillar Industry, Catalyzing Valuation Repair, Guotai Sci-Tech Innovation Pharma ETF (589720) Surges Over 3.4% in Single Day

Guotai (589720) Innovation Drug ETF’s intraday latest increase exceeds 3.4%, with a daily trading volume of 90.0569 million yuan. The fund’s latest size is 1.244 billion yuan, showing a significant rebound, active trading, and steady scale characteristics.

【Event Analysis】

Policy upgrade (biopharmaceuticals as an emerging pillar industry): The 2026 government work report explicitly designates biopharmaceuticals as an “emerging pillar industry” for the first time and proposes implementing industrial innovation projects during the 14th Five-Year Plan to create a new engine of productive force. This marks a top-level design upgrade, combined with supporting policies such as equipment upgrades and medical insurance payment reforms, strengthening the industry’s long-term growth certainty.

Overseas expansion of innovative drugs and the value re-evaluation of BD models: Leading companies like Hengrui and Cinda continue to achieve large-scale BD transactions (initial payments exceeding $500 million). Huatai Securities points out that the market underestimates the sustainability of milestone revenue and sales sharing cash flow, and the “Chinese-style BD model” is driving valuation logic from pipeline discounting to profitability predictability restructuring.

Cutting-edge technological clinical breakthroughs are being rapidly realized: Junshi Biosciences’ PD-1 subcutaneous formulation application, BaiLi Tianheng’s FIC-class ARC drug BL-ARC002 approved for clinical trials, and the Chinese Academy of Sciences/Long March Hospital achieving the world’s first minimally invasive stem cell regenerative pancreatic transplantation. Multiple breakthroughs verify domestic hard technology R&D capabilities, accelerating clinical translation and international recognition.

【Market Outlook】

CITIC Securities: Recently, the innovation drug sector has continued to rebound, especially the overall strength of IO (immuno-oncology) pipelines, which is expected to drive valuation recovery in the sector. The market currently perceives higher cost-effectiveness in innovation drug allocation, coupled with gradually clear Q1 performance expectations, creating phased allocation opportunities. Focus on innovative drug companies with solid clinical progress and internationalization capabilities, paying attention to core indicators such as R&D pipeline richness, clinical advancement pace, and overseas licensing progress.

CICC: By 2026, global geopolitical uncertainties will increase, and the short-term market will be significantly influenced by international situations and trading structures. However, the long-term innovation trend in the pharmaceutical industry remains unchanged. Under industry cleanup, companies with technological barriers and global capabilities are more likely to attract long-term capital. Key areas to watch include the industrialization and overseas expansion of ADCs, bispecific antibodies, small nucleic acids, and GLP-1 weight-loss drugs.

The Guotai (589720) Innovation Drug ETF tracks the Innovation Drug Index (950161), which has a daily limit of 20%. The index focuses on the field of new drug research driven by technological innovation, with constituent stocks comprising listed companies engaged in innovative drug research, development, and manufacturing. The index emphasizes high growth and innovation in the biopharmaceutical industry, reflecting the performance and market value of related enterprises in new drug R&D.

Risk Reminder: Mentioned individual stocks are for industry event analysis only and do not constitute any stock recommendation or investment advice. Short-term index fluctuations are for reference only and do not predict future performance, nor do they constitute a promise or guarantee of fund performance. Views may change with market conditions and do not constitute investment advice or guarantees. The risk-return characteristics of funds vary; investors should carefully read the fund legal documents, fully understand product features, risk levels, and income distribution principles, and choose products matching their risk tolerance. Please consult legal documents for fund fee rates.

Daily Economic News

（Editor: Zhang Xiaobo）

【Disclaimer】This article only reflects the author’s personal views and is not related to Hexun.com. Hexun maintains neutrality regarding statements and opinions in the article and does not provide any explicit or implicit guarantees on the accuracy, reliability, or completeness of the content. Readers should use it for reference only and bear all responsibilities themselves. Email: news_center@staff.hexun.com